AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33966730
Drug: No scar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No scar treatment
Trial: 36126648
Drug: Hemostatic spray
RxNorm normalized name: gas pressurized hemostatic spray device and acces.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemostatic spray
Trial: 33556464
Drug: Early AIT
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early AIT with intravenous anakinra (100 mg every 8 hours for 3 days, with tapering) alone
Trial: 33556464
Drug: Early AIT
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early AIT with intravenous anakinra plus glucocorticoid (intravenous methylprednisolone, 1-2 mg/kg daily, with tapering)
Trial: 33556464
Drug: Late rescue
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late rescue treatment (anakinra or tocilizumab)
Trial: 35019020
Drug: Chlorhexidine 0.12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 0.12% spray
Trial: 33051423
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (62±2 mL/(kg·min))
Trial: 33051423
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (72±2 mL/(kg·min))
Trial: 33051423
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (82±2 mL/(kg·min))
Trial: 35007749
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment with a hook plate
Trial: 35007749
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (physiotherapy)
Trial: 35581660
Drug: Transmucosal diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmucosal diamorphine (buccal and intranasal routes)
Trial: 35686330
Drug: aprocitentan 12.5
RxNorm normalized name: aprocitentan 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aprocitentan 12.5 mg
Trial: 33228621
Drug: Higher perceived
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher perceived susceptibility of oral diseases
Trial: 33228621
Drug: Higher perceived
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher perceived severity of oral diseases
Trial: 33228621
Drug: Flossing weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flossing weekly
Trial: 33228621
Drug: Stronger perceived
RxNorm normalized name: Strongid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stronger perceived susceptibility, greater severity of oral diseases, less performing of oral health behaviors, higher DMFT score
Trial: 33031757
Drug: Cobitolimod 2
RxNorm normalized name: Cobitolimod
DrugBank: Cobitolimod (DB14819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobitolimod 2 × 250 mg
Trial: 33031757
Drug: Cobitolimod 2
RxNorm normalized name: Cobitolimod
DrugBank: Cobitolimod (DB14819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobitolimod 2 × 31 mg
Trial: 33031757
Drug: Cobitolimod 2
RxNorm normalized name: Cobitolimod
DrugBank: Cobitolimod (DB14819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobitolimod 2 × 125 mg
Trial: 33031757
Drug: Cobitolimod 4
RxNorm normalized name: Cobitolimod
DrugBank: Cobitolimod (DB14819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobitolimod 4 × 125 mg
Trial: 33978491
Drug: 50 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g/day dried plum
Trial: 33978491
Drug: 100 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g/day dried plum
Trial: 32868360
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of ivermectin-based mass drug administration (MDA)
Trial: 32868360
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of ivermectin-based mass drug administration (MDA)
Trial: 32868360
Drug: One-dose and
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-dose and two-dose MDA
Trial: 33503305
Drug: Single-agent azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-agent azacitidine
Trial: 32067657
Drug: Combined laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined laser therapy and chiropractic care
Trial: 36297102
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg.kg−1)
Trial: 33722384
Drug: Topical ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules
Trial: 33829308
Drug: Oxytocin nasal
RxNorm normalized name: oxytocin Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin nasal spray (24 IU intranasal administration)
Trial: 35397638
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (160 IU/1.6 mL)
Trial: 35757899
Drug: Hybrid closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid closed-loop (HCL) therapy using Medtronic MiniMed™ 670G system
Trial: 32226019
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (10,000 lux)
Trial: 32005282
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose hUC-MSCs (2.5 million cells/kg)
Trial: 32005282
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose hUC-MSCs (5 million cells/kg)
Trial: 32005282
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional supportive treatments alone)
Trial: 33064057
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (Group 1)
Trial: 33438437
Drug: Alirocumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab with achieved LDL-C <25 mg/dL
Trial: 33438437
Drug: Alirocumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab with achieved LDL-C 25 to 50 mg/dL
Trial: 33438437
Drug: Alirocumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab with achieved LDL-C >50 mg/dL
Trial: 32728111
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of orthokeratology (OK) and 0.01% atropine solution
Trial: 32728111
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with orthokeratology (OK)
Trial: 33472855
Drug: Tocilizumab (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (single intravenous infusion of 8 mg/kg) plus standard care (n=65)
Trial: 32371120
Drug: Micro-training (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-training (four 15-min strength and four 15-min endurance bouts weekly)
Trial: 32371120
Drug: Classical-training (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical-training (one 60-min strength and one 60-min endurance training session weekly)
Trial: 32371120
Drug: Control-group (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control-group (two 60-min standard military physical training sessions weekly)
Trial: 36433884
Drug: Attention Bias
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention Bias Modification Treatment (ABMT) as an add-on to regular inpatient treatment, involving two pretreatment training sessions and eight biweekly sessions.
Trial: 33618522
Drug: HART-CT (concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HART-CT (concomitant hyperfractionated radiotherapy with chemotherapy)
Trial: 34159560
Drug: Colchicine 500
RxNorm normalized name: Colchicine 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 500 mcg od
Trial: 32880057
Drug: anodal-left PFC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anodal-left PFC tDCS plus placebo medication
Trial: 32880057
Drug: escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram 10 mg/day for 3 weeks and 20 mg/day thereafter plus sham tDCS
Trial: 32880057
Drug: placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo medication plus sham tDCS
Trial: 32243492
Drug: Inclisiran 300
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 300 mg single dose
Trial: 32243492
Drug: Inclisiran 500
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 500 mg single dose
Trial: 32243492
Drug: Inclisiran 100
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 100 mg double dose
Trial: 32243492
Drug: Inclisiran 200
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 200 mg double dose
Trial: 32243492
Drug: Inclisiran 300
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 300 mg double dose
Trial: 32243492
Drug: Placebo single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single dose
Trial: 32243492
Drug: Placebo double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo double dose
Trial: 32243492
Drug: Inclisiran (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (all dosing regimens)
Trial: 33892624
Drug: Impairments in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impairments in activities of daily living
Trial: 35304647
Drug: Targeted tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted tidal volume of 4 ml/kg
Trial: 35304647
Drug: Targeted tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted tidal volume of 5 ml/kg
Trial: 35304647
Drug: Targeted tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted tidal volume of 6 ml/kg
Trial: 34286472
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D
Trial: 33371148
Drug: Active NAE
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active NAE therapy (n=20)
Trial: 34979631
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.3 mg/kg IV ketamine and 40.0 mg IV parecoxib (group K-P)
Trial: 34979631
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg IV ketamine alone (group K)
Trial: 35580635
Drug: Oxygen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen (10 L per minute by simple, tight‐fitting face mask until delivery)
Trial: 33609057
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil injection (test product)
Trial: 33609057
Drug: ROPION (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROPION (reference drug)
Trial: 32032804
Drug: Active gesture
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active gesture intervention (Visual Action Therapy)
Trial: 35063214
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplement (1000 IU + 25 g canola oil daily, n=31)
Trial: 35063214
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D fortified oil (placebo tablet + 25 g canola oil fortified with 1000 IU vitamin D daily, n=30)
Trial: 35063214
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo tablet + 25 g canola oil, n=32)
Trial: 34882076
Drug: Indapamide retard
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide retard 1.5 mg in the morning and valsartan 160 mg in the evening (Group 2)
Trial: 34882076
Drug: Indapamide retard
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide retard 1.5 mg in the morning and valsartan 80 mg in the morning and evening (Group 3)
Trial: 35459688
Drug: Mindfulness-based supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based supportive therapy (MBST)
Trial: 33107050
Drug: Common treatment
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common treatment area (owner absent)
Trial: 35341011
Drug: Common postoperative
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common postoperative treatment
Trial: 32719254
Drug: Concomitant boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant boost radiotherapy (CBRT) - 45 Gy/25#/5-weeks and 18 Gy/10# concomitant boost in the last 2-weeks, total dose 63 Gy.
Trial: 32719254
Drug: Concomitant boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant boost with concurrent chemoradiation (CBRT + CCT) - CBRT with cisplatin 75 mg/m2 on day 1, 17, and 34.
Trial: 32719254
Drug: Standard fractionation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fractionation chemoradiation with concomitant chemotherapy (CFRT + CCT) - 64 Gy/32#/6.2 weeks, concurrent with cisplatin 75 mg/m2 on day 1, 22, and 42.
Trial: 32371433
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg at Weeks 0/2/4, then 200 mg every 2 weeks up to 96 weeks
Trial: 35815022
Drug: BEAM intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BEAM intervention (10-week program including weekly videos, activities based on Unified Protocol therapy modules, telehealth group sessions, and online support forum)
Trial: 35815022
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) control group
Trial: 38704973
Drug: Stress management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress management treatment
Trial: 35083557
Drug: Meperidine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 12.5 mg (1 mL) added to 0.5% 10 mg (2 mL) of hyperbaric bupivacaine
Trial: 35083557
Drug: Sufentanil 5
RxNorm normalized name: SUFentanil 50 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 5 μg (1 mL) added to 0.5% 10 mg (2 mL) of hyperbaric bupivacaine
Trial: 36163869
Drug: Ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (420 mg once daily)
Trial: 34043412
Drug: Neoadjuvant capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant capecitabine and oxaliplatin (CAPOX) followed by concurrent radiation and capecitabine (CAPRT)
Trial: 34187081
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Treatment (NRT)
Trial: 34485877
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite 100 mcg/day
Trial: 36008062
Drug: Web-based psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based psychoeducational intervention integrating dialectical behavioural therapy and empowerment approach
Trial: 36007135
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL sodium bicarbonate in 240 mL isotonic nasal irrigation twice daily for 14 days
Trial: 36007135
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL povidone-iodine 10% in 240 mL isotonic nasal irrigation twice daily for 14 days
Trial: 36007135
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily irrigation (regardless of additive)
Trial: 34704970
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin administered every 8 hours for 6 doses
Trial: 34704970
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered every 8 hours for 6 doses
Trial: 32458980
Drug: DIM 100
RxNorm normalized name: DIM-SA
DrugBank: Succimer (DB00566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DIM 100 mg × 1/day for 1 year
Trial: 33287868
Drug: Acupuncture (Jin’s
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (Jin’s three-needle acupuncture) as adjunctive therapy with methadone maintenance therapy (MMT) for 30 min per session, 18 sessions over 6 weeks (3 per week).
Trial: 36155742
Drug: SMS text
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS text messages to parents (twice daily for 1 year)
Trial: 33790343
Drug: Upper extremity
RxNorm normalized name: lymphedema garments, upper extremity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upper extremity treatment with sonification techniques
Trial: 32788051
Drug: Dalfampridine (4-AP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine (4-AP, 10 mg BID)
Trial: 33407796
Drug: APOSEC (cell-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APOSEC (cell-free secretome of peripheral blood mononuclear cells) applied topically three times weekly for 4 weeks.
Trial: 33407796
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied topically three times weekly for 4 weeks.
Trial: 34187130
Drug: Tualang honey
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tualang honey nasal dressing (2 mL)
Trial: 34187130
Drug: Steroid nasal
RxNorm normalized name: Corticosteroid nasal preparations for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid nasal dressing (triamcinolone 20 mg/mL, 2 mL)
Trial: 32200659
Drug: QL0902 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL0902 (50 mg subcutaneous injection)
Trial: 32200659
Drug: Reference Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reference Etanercept (50 mg subcutaneous injection)
Trial: 33412596
Drug: Heparin (low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (low-molecular-weight heparin or unfractionated heparin)
Trial: 43637190
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g oral dose of amoxicillin (Amoxil®)
Trial: 43637190
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g oral dose of amoxicillin with 100 mg of sodium diclofenac (Voltaren®)
Trial: 35319989
Drug: Combined high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined high-dose radiotherapy and adoptive NK cell transfer
Trial: 35183991
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (60 Gy and 45 Gy)
Trial: 34162016
Drug: Dinoprostone vaginal
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone vaginal insert (DVI) with adjunctive sweeping of membranes (ASM)
Trial: 34047872
Drug: 2% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% CHX gel + AgNP
Trial: 36428014
Drug: MEDIC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDIC treatment (patient education, supervised exercise, weight loss, insoles, pain medication)
Trial: 34519161
Drug: E‐WAA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E‐WAA treatment
Trial: 33794865
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg) once a day for 3 months
Trial: 33794865
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg) and Placebo
Trial: 38865168
Drug: Placebo (Ringer's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Ringer's solution)
Trial: 33609021
Drug: Propolis extract
RxNorm normalized name: PROPOLIS EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis extract gel (2% propolis, 0.2% ascorbic acid, 0.2% tocopherol acetate) applied 3 times/day for a week
Trial: 33609021
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied 3 times/day for a week
Trial: 34992091
Drug: DCVAC/OvCa parallel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCVAC/OvCa parallel to chemotherapy (Group A)